155 related articles for article (PubMed ID: 32048798)
1. ITTREAT (Integrated Community Test - Stage - TREAT) Hepatitis C service for people who use drugs: Real-world outcomes.
O'Sullivan M; Jones AM; Gage H; Jordan J; MacPepple E; Williams H; Verma S
Liver Int; 2020 May; 40(5):1021-1031. PubMed ID: 32048798
[TBL] [Abstract][Full Text] [Related]
2. Excellent hepatitis C virus cure rates despite increasing complexity of people who use drugs: Integrated-Test-stage Treat study final outcomes.
O'Sullivan M; Jones AM; Mourad A; Haddadin Y; Verma S
J Viral Hepat; 2024 Feb; 31(2):66-77. PubMed ID: 38018328
[TBL] [Abstract][Full Text] [Related]
3. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.
Read P; Lothian R; Chronister K; Gilliver R; Kearley J; Dore GJ; van Beek I
Int J Drug Policy; 2017 Sep; 47():209-215. PubMed ID: 28587943
[TBL] [Abstract][Full Text] [Related]
4. Direct-acting antiviral therapy for hepatitis C infection among people receiving opioid agonist treatment or heroin assisted treatment.
Scherz N; Bruggmann P; Brunner N
Int J Drug Policy; 2018 Dec; 62():74-77. PubMed ID: 30368101
[TBL] [Abstract][Full Text] [Related]
5. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy.
Macías J; Morano LE; Téllez F; Granados R; Rivero-Juárez A; Palacios R; Ríos M; Merino D; Pérez-Pérez M; Collado A; Figueruela B; Morano A; Freyre-Carrillo C; Martín JM; Rivero A; García F; Pineda JA;
J Hepatol; 2019 Jul; 71(1):45-51. PubMed ID: 30853642
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort.
Rossi C; Butt ZA; Wong S; Buxton JA; Islam N; Yu A; Darvishian M; Gilbert M; Wong J; Chapinal N; Binka M; Alvarez M; Tyndall MW; Krajden M; Janjua NZ;
J Hepatol; 2018 Nov; 69(5):1007-1014. PubMed ID: 30142429
[TBL] [Abstract][Full Text] [Related]
7. Improvement of chronic HCV infection-related depression, anxiety, and neurocognitive performance in persons achieving SVR-12: A real-world cohort study.
Kaur H; Dhiman RK; Kulkarni AV; Premkumar M; Singh V; Duseja AK; Grover S; Grover GS; Roy A; Verma N; De A; Taneja S; Mehtani R; Mishra S; Kaur H
J Viral Hepat; 2022 May; 29(5):395-406. PubMed ID: 35266624
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life in hepatitis C patients who achieve sustained virological response to direct-acting antivirals: a comparison with the general population.
Juanbeltz R; Castilla J; Martínez-Baz I; O'Leary A; Sarobe M; San Miguel R
Qual Life Res; 2019 Jun; 28(6):1477-1484. PubMed ID: 30666549
[TBL] [Abstract][Full Text] [Related]
9. Changes in Health-related Quality of Life for Hepatitis C Virus-Infected People Who Inject Drugs While on Opioid Agonist Treatment Following Sustained Virologic Response.
Gormley MA; Akiyama MJ; Rennert L; Howard KA; Norton BL; Pericot-Valverde I; Muench S; Heo M; Litwin AH
Clin Infect Dis; 2022 May; 74(9):1586-1593. PubMed ID: 34331539
[TBL] [Abstract][Full Text] [Related]
10. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?
Christensen S; Buggisch P; Mauss S; Böker KHW; Schott E; Klinker H; Zimmermann T; Weber B; Reimer J; Serfert Y; Wedemeyer H
Addiction; 2018 May; 113(5):868-882. PubMed ID: 29359361
[TBL] [Abstract][Full Text] [Related]
11. Direct-acting antiviral treatment for hepatitis C, reinfection and mortality among people attending an inner-city community health centre in Victoria, Canada.
Selfridge M; Cunningham EB; Milne R; Drost A; Barnett T; Lundgren K; Guarasci K; Grebely J; Fraser C
Int J Drug Policy; 2019 Oct; 72():106-113. PubMed ID: 31178254
[TBL] [Abstract][Full Text] [Related]
12. Long-term changes on health-related quality of life in patients with chronic hepatitis C after viral clearance with direct-acting antiviral agents.
Goñi Esarte S; Juanbeltz R; Martínez-Baz I; Castilla J; San Miguel R; Herrero JI; Zozaya JM
Rev Esp Enferm Dig; 2019 Jun; 111(6):445-452. PubMed ID: 31066286
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C reinfection following successful direct-acting antiviral therapy among patients attending a multidisciplinary treatment centre for people who use drugs in Zurich, Switzerland.
Falcato L; Bernardini C; Bruggmann P
Int J Drug Policy; 2021 Oct; 96():103434. PubMed ID: 34511311
[TBL] [Abstract][Full Text] [Related]
14. High Effectiveness of Broad Access Direct-Acting Antiviral Therapy for Hepatitis C in an Australian Real-World Cohort: The REACH-C Study.
Yee J; Carson JM; Hajarizadeh B; Hanson J; O'Beirne J; Iser D; Read P; Balcomb A; Doyle JS; Davies J; Martinello M; Marks P; Dore GJ; Matthews GV;
Hepatol Commun; 2022 Mar; 6(3):496-512. PubMed ID: 34729957
[TBL] [Abstract][Full Text] [Related]
15. A platform in the use of medicines to treat chronic hepatitis C (PLATINUM C): protocol for a prospective treatment registry of real-world outcomes for hepatitis C.
Ramsay J; Marsh J; Pedrana A; Andric N; Norman R; Cheng W; Webb S; Zeps N; Bellgard M; Graves T; Hellard M; Snelling T
BMC Infect Dis; 2020 Oct; 20(1):802. PubMed ID: 33121439
[TBL] [Abstract][Full Text] [Related]
16. High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study.
Mancuso ME; Linari S; Santagostino E; Bartolozzi D; D'Ambrosio R; Borghi M; Lampertico P; Peyvandi F; Castaman G; Aghemo A
Liver Int; 2020 May; 40(5):1062-1068. PubMed ID: 31876354
[TBL] [Abstract][Full Text] [Related]
17. Community-Based Assessment and Treatment of Hepatitis C Virus-Related Liver Disease, Injecting Drug and Alcohol Use Amongst People Who Are Homeless: A Systematic Review and Meta-Analysis.
Hashim A; Macken L; Jones A; McGeer M; Aithal G; Verma S
Int J Drug Policy; 2021 Oct; 96():103342. PubMed ID: 34210551
[TBL] [Abstract][Full Text] [Related]
18. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.
Saeed S; Strumpf EC; Moodie EE; Young J; Nitulescu R; Cox J; Wong A; Walmsely S; Cooper C; Vachon ML; Martel-Laferriere V; Hull M; Conway B; Klein MB;
J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29116684
[TBL] [Abstract][Full Text] [Related]
19. Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland.
Bachofner J; Valli PV; Bergamin I; Kröger A; Künzler P; Baserga A; Braun DL; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens J; The Swiss Hepatitis C Cohort Study
Swiss Med Wkly; 2018; 148():w14560. PubMed ID: 29376557
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C (HCV) therapy for HCV mono-infected and HIV-HCV co-infected individuals living in Nepal.
Kc S; Murphy H; Dixit S; Rai A; Pradhan B; Lagrange-Xelot M; Karki N; Dureault A; Karmacharya U; Panthi S; Tulachan N; Kc P; Kc A; Rajbhandari R; Trotter AB; Gölz J; Pradat P; Trépo C; Creac'H P
PLoS Negl Trop Dis; 2020 Dec; 14(12):e0008931. PubMed ID: 33326423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
